Early Insulin Treatment to Prevent Cardiovascular Disease in Prediabetes and Overt Diabetes

Abstract

Type 2 diabetes mellitus (DM) is a major risk factor for cardiovascular disease (CVD), and CVD represents the leading cause of death in people with type 2 DM. The cardiovascular risk is increased long before diabetes is diagnosed, in the prediabetes stage, when impaired fasting glucose (IFG) and/or impaired glucose tolerance (IGT) develop. These stages are characterized by dysglycemia, defined as any elevated fasting or postprandial glycemia, extending from the normal range into diabetic range, associated with an increased risk of CVD. Due to metabolic memory demonstrated for type 2 DM as well, early interventions addressed to achieve and maintain glycemic control are required for long-term benefits in terms of both microvascular and macrovascular complications. The recommendation of early insulin therapy in type 2 DM is sustained by its pleiotropic effects, which may be cardioprotective and potentially anti-atherosclerotic. Insulin therapy in prediabetes and earlier in type 2 DM, could be a strategy in preventing cardiovascular disease and type 2 DM progression. To test this hypothesis, a large trial has been designed. Outcome Reduction with an Initial Glargine Intervention trial (ORIGIN) is an international, multicenter, randomized controlled, 2 × 2 factorial trial, investigating the possibility to prevent cardiovascular morbidity and mortality in people with type 2 DM, IGT, and/or IFG, and high cardiovascular risk by treating the normoglycemia with either insulin glargine or omega-3 fatty acid, compared to the standard intervention.

prediabetes - insulin - dysglycemia - cardiovascular disease

References

• 1 International Diabetes Federation . Diabetes Atlas, third edition, 2007. , Available from http://www.eatlas.idf.org , Accessed on 23 August 2008
• 2 International Diabetes Federation . Diabetes and Cardiovascular Disease: Time to Act 2001. , Available from http://http//:www.idf.org , Accessed on 23 August 2008
• 3 Fox CS, Coady S, Sorlie PD, D’Agostino  Sr  RB, Pencina MJ, Vasan RS, Meigs JB, Levy D, Savage PJ. Increasing cardiovascular disease burden due to diabetes mellitus: The Framingham Heart Study.  Circulation. 2007;  115 1544-1550
• 4 American Diabetes Association, National Heart, Lung, and Blood Institute, Juvenile Diabetes Foundation International, National Institute of Diabetes and Digestive and Kidney Diseases, American Heart Association . Diabetes mellitus: a major risk factor for cardiovascular disease: a joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association.  Circulation. 1999;  100 1132-1133
• 5 Gerich JE. Type 2 diabetes mellitus is associated with multiple cardiometabolic risk factors.  Clin Cornerstone. 2007;  8 53-68
• 6 Expert Panel on Detection, Evaluation. Treatment of High Blood Cholesterol in Adults . Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III).  JAMA. 2001;  285 2486-2497
• 7 Buse JB, Ginsberg HN, Bakris GL, Clark NG, Costa F, Eckel R, Fonseca V, Gerstein HC, Grundy S, Nesto RW, Pignone MP, Plutzky J, Porte D, Redberg R, Stitzel KF, Stone NJ. Primary prevention of cardiovascular diseases in people with diabetes mellitus: A scientific statement from the American Heart Association and the Amercian Diabetes Association.  Diabetes Care. 2007;  30 162-172
• 8 Ho JE, Paultre F, Mosca L. Diabetes mellitus a cardiovascular disease risk equivalent for fatal stroke in women? Data from the women's pooling project.  Stroke. 2003;  34 2812-2816
• 9 Jeerakathil T, Johnson JA, Simpson SH, Majumdar SR. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes. A population-based cohort study.  Stroke. 2007;  38 1739-1743
• 10 Yusuf S, Hawken S, Ounpuu S. on behalf of the INTERHEART Study Investigators . Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study.  Lancet. 2004;  364 937-952
• 11 Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction.  N Engl J Med. 1998;  339 229-234
• 12 Pajunen P, Koukkunen H, Ketonen M, Jerkkola T, Immonen-Räihä P, Kärjä-Koskenkari P, Kuulasmaa K, Palomäki P, Mustonen J, Lehtonen A, Arstila M, Vuorenmaa T, Lehto S, Miettinen H, Torppa J, Tuomilehto J, Kesäniemi YA, Pyörälä K, Salomaa V. Myocardial infarction in diabetic and non-diabetic persons with and without prior myocardial infarction: the FINAMI Study.  Diabetologia. 2005;  48 2519-2524
• 13 Schramm TK, Gislason GH, Køber L, Rasmussen S, Rasmussen JN, Abildstrøm SZ, Hansen ML, Folke F, Buch P, Madsen M, Vaag A, Torp-Pedersen C. Diabetes patients requiring glucose-lowering therapy and nondiabetics with a prior myocardial infarction carry the same cardiovascular risk. A population study of 3.3 million people.  Circulation. 2008;  117 1945-1954
• 14 American Diabetes Association . Diagnosis and Classification of Diabetes Mellitus.  Diabetes Care. 2008;  31 S55-S60
• 15 IDF/WHO . Definition and diagnosis of diabetes mellitus and intermediate hyperglycemia. 2006; 
• 16 Haffner SM, Stern MP, Hazuda HP, Mitchell BD, Patterson JK. Cardiovascular risk factors in confirmed prediabetic individuals.  Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA. 1990;  263 2893-2898
• 17 Hu FB, Stampfer MJ, Haffner SM, Solomon CG, Willett WC, Manson JE. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes.  Diabetes Care. 2002;  25 1129-1134
• 18 Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European prospective investigation of cancer and nutrition (EPIC-Norfolk).  BMJ. 2001;  322 15-18
• 19 Khaw KT, Wareham N, Luben R, Bingham S, Oakes S, Welch A, Day N. Association of hemoglobin A1c with cardiovascular disease and mortality in adults: The European prospective investigation into cancer in Norfolk.  Ann Intern Med. 2004;  141 413-420
• 20 Gerstein HC. Glucose: a continuous risk factor for cardiovascular disease.  Diabetic Med. 1997;  14 S25-S31
• 21 Simmons RK, Sharp S, Boekholdt SM, Sargeant LA, Khaw KT, Wareham NJ, Griffin SJ. Evaluation of the Framingham risk score in the European Prospective Investigation of Cancer-Norfolk cohort: does adding glycated hemoglobin improve the prediction of coronary heart disease events?.  Arch Intern Med. 2008;  168 1209-1216
• 22 Gerstein HC, Yusuf S. Dysglycaemia and risk of cardiovascular disease.  Lancet. 1996;  347 949-950
• 23 Gerstein HC, Capes SE. Dysglycemia: A Key Cardiovascular Risk Factor.  Seminars in Vascular Medicine. 2002;  2 165-174
• 24 Bjornholt JV, Erikssen G, Aaser E, Sandvik L, Nitter-Hauge S, Jervell J, Erikssen J, Thaulow E. Fasting blood glucose: an underestimated risk factor for cardiovascular death.  Diabetes Care. 1999;  22 45-49
• 25 Coutinho M, Gerstein HC, Wang Y, Yusuf S. The relationship between glucose and incident cardiovascular events. A meta regression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years.  Diabetes Care. 1999;  22 233-240
• 26 Myint PK, Sinha S, Wareham NJ, Bingham SA, Luben RN, Welch AA, Khaw KT. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation Into Cancer (EPIC)–Norfolk Prospective Population Study: A Threshold Relationship?.  Stroke. 2007;  38 271-275
• 27 Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: The Atherosclerosis Risk in Communities Study.  Arch Intern Med. 2005;  165 1910-1916
• 28 Selvin E, Coresh J, Shahar E, Zhang L, Steffes M, Sharrett A. Glycaemia (haemoglobin A) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study.  Lancet Neurol. 2005;  12 821-826
• 29 Nichols GA, Hillier TA, Brown JB. Normal fasting plasma glucose and risk of type 2 diabetes diagnosis.  Am J Med. 2008;  121 519-524
• 30 Nathan DM, Davidson MB, Defronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B. Impaired Fasting Glucose and Impaired Glucose Tolerance. Implications for care.  Diabetes Care. 2007;  30 753-759
• 31 Rasmussen SS, Glumer C, Sandbaek A, Lauritzen T, Borch-Johnsen K. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark.  Diabetologia. 2007;  50 293-297
• 32 Asia Pacific Cohort Studies Collaboration . Blood glucose and risk of cardiovascular disease in the Asia Pacific region.  Diabetes Care. 2004;  27 2836-2842
• 33 Park S, Barrett-Connor E, Wingard DL, Shan J, Edelstein S. GHb is a better predictor of cardiovascular disease than fasting or postchallenge plasma glucose in women without diabetes:the Rancho Bernardo Study.  Diabetes Care. 1996;  19 450-456
• 34 Barrett-Connor E, Ferrara A. Isolated postchallenge hyperglycemia and the risk of fatal cardiovascular disease in older women and men: the Rancho Bernardo Study.  Diabetes Care. 1998;  21 1236-1239
• 35 Wedick N, Wingard D, Barrett-Connor E. A prospective study to identify the best glycemic predictors of nonfatal coronary heart disease (CHD) and cardiovascular disease (CVD) mortality; the Rancho Bernardo Study.  Am J Epidemiol. 2000;  151 ((Suppl)) S38
• 36 Kanaya AM, Christina L, Fyr W, Rekeneire N de, Shorr RI, Schwartz AV, Goodpaster BH, Newman AB, Harris T, Barrett-Connor E. Predicting the development of diabetes in older adults: The derivation and validation of a prediction rule.  Diabetes Care. 2005;  28 404-408
• 37 Grundy SM, Brewer  Jr  HB, Cleeman JI, Smith  Jr  SC, Lenfant C. for the Conference Participants. . Definition of Metabolic Syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association Conference on Scientific Issues Related to Definition.  Circulation. 2004;  109 433-438
• 38 International Diabetes Federation . The IDF consensus worldwide definition of the metabolic syndrome. http://available at www.idf.org/idf_metasyndrome_definition.pdf , Accessed 24 August 2008
• 39 Després JP, Lemieux I. Abdominal obesity and metabolic syndrome.  Nature. 2006;  444 881-887
• 40 Despres JP, Poirier P, Bergeron J, Tremblay A, Lemieux I, Almeras N. From individual risk factors and the metabolic syndrome to global cardiometabolic risk.  Eur Heart J Suppl. 2008;  10 ((Suppl B)) B24-B33
• 41 The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group . Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.  N Engl J Med. 2005;  353 2643-2653
• 42 Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes.  N Engl J Med. 2008;  358 580-591
• 43 Ohkubo Y, Kishikawa H, Araki E, Miyata T, Isami S, Motoyoshi S, Kojima Y, Furuyoshi N, Shichiri M. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.  Diabetes Res Clin Pract. 1995;  28 103-117
• 44 UK Prospective Diabetes Study (UKPDS) Group . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).  Lancet. 1998;  352 837-853
• 45 UK Prospective Diabetes Study (UKPDS) Group . Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34).  Lancet. 1998;  352 854-865
• 46 Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2006;  29 1963-1972
• 47 IDF Clinical Guidelines Task Force . Global guideline for Type 2 diabetes. 2005.  , Available from http://http//:www.idf.org , Accessed on 30 August 2008
• 48 Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2009;  32 1-11
• 49 Malmberg K, Ryden L, Hamsten A, Herlitz J, Waldenstrom A, Wendel H. Effects of insulin treatment on cause specific one-year mortality and morbidity in diabetic patients with acute myocardial infarctions.  Eur Heart J. 1996;  17 1337-1344
• 50 Malmberg K. Prospective randomized study of intensive insulin treatment of long-term survival after acute myocardial infarction in patients with diabetes mellitus.  Br Med J. 1997;  314 1512-1515
• 51 Stettler C, Allemann S, Jüni P, Cull CA, Holman RR, Egger M, Krähenbühl S, Diem P. Glycemic control and macrovascular disease in types 1 and 2 diabetes mellitus: Meta-analysis of randomized trials.  Am Heart J. 2006;  152 27-38
• 52 Selvin E, Marinopoulos S, Berkenblit G, Rami T, Brancati FL, Powe NR, Goldenet SH. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus.  Ann Intern Med. 2004;  141 421-431
• 53 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes.  N Engl J Med. 2008;  359 1-13
• 54 The ADVANCE Collaborative Group . Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.  N Engl J Med. 2008;  358 2560-2572
• 55 The Action to Control Cardiovascular Risk in Diabetes Study Group. . Effects of intensive glucose lowering in type 2 diabetes.  N Engl J Med. 2008;  358 2545-2559
• 56 Duckworth WC. Cardiovascular outcomes by glycemic control treatment arm. ADA Meeting, San Francisco 2008
• 57 UK Prospective Diabetes Study Group . UK prospective diabetes study 16. Overview of 6 years’ therapy of type II diabetes. A progressive disease.  Diabetes. 1995;  44 1249-1258
• 58 Tibaldi J. Preserving insulin secretion in type 2 diabetes mellitus.  Expert Rev Endocrinol Metab. 2008;  3 147-159
• 59 Kahn SE. Clinical review 135: The importance of beta-cell failure in the development and progression of type 2 diabetes.  J Clin Endocrinol Metab. 2001;  86 4047-4058
• 60 Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes.  Diabetes Care. 2004;  27 1535-1540
• 61 Nathan DM, Buse JB, Davidson MB, Heine RJ, Holman RR, Sherwin R, Zinman B. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes.  Diabetes Care. 2008;  31 173-175
• 62 Westphal SA, Palumbo PJ. A case for introducing insulin early in the treatment of type 2 diabetes mellitus.  Insulin. 2006;  1 65-69
• 63 Ilkova H, Glaser B, Tunckale A, Bagriacik N, Cerasi E. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.  Diabetes Care. 1997;  20 1353-1356
• 64 Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng JP. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.  Diabetes Care. 2004;  27 2597-2602
• 65 Noh YN, Lee SM, Kim EJ, Kim DY, Lee H, Lee JH, Ju-Han Lee, Park SY, Koo JH, Wang JH, Lim IJ, Choi SB. Improvement of cardiovascular risk factors in patients with type 2 diabetes after long-term continuous subcutaneous insulin infusion.  Diabetes/Metabolism Res Rev. 2008;  24 384-391
• 66 Park S, Choi SB. Induction of long-term normoglycemia without medication in Korean type 2 diabetes patients after continuous subcutaneous insulin infusion therapy.  Diabetes Metab Res Rev. 2003;  19 124-130
• 67 Weng J, Li Y, Xu W, Shi L, Zhang Q, Zhu D, Hu Y, Zhou Z, Yan X, Tian H, Ran X, Luo Z, Xian J, Yan L, Li F, Zeng L, Chen Y, Yang L, Yan S, Lin J, Li M, Fu Z, Cheng H. Effect of intensive insulin therapy on β-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial.  Lancet. 2008;  371 1753-1760
• 68 Nauck MA, Meier JJ, Creutzfeldt W. Incretins and their analogues as new antidiabetic drugs.  Drug News Perspect. 2003;  16 413-422
• 69 Tews D, Werner U, Eckel J. Enhanced protection against cytokine- and fatty acid-induced apoptosis in pancreatic beta cells by combined treatment with glucagon-like peptide-1 receptor agonists and insulin analogues.  Horm Metab Res. 2008;  40 172-180
• 70 Scarlett JA, Gray RS, Griffin J, Olefsky JM, Kolterman OG. Insulin treatment reverses the insulin resistance of type II diabetes mellitus.  Diabetes Care. 1982;  5 353-363
• 71 Zhao L, Sun D, Cao F, Yin T, Wang H. Can insulin resistance be reversed by insulin therapy?.  Med Hypoth. 2009;  72 34-35
• 72 Vinik AI. Benefits of early initiation of insulin therapy to long-term goals in type 2 diabetes mellitus.  Insulin. 2006;  1 2-12
• 73 Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Use of insulin to improve glycemic control in diabetes mellitus.  Cardiovascul Drugs Ther. 2008;  22 241-251
• 74 Dandona P, Chaudhuri A, Ghanim H, Mohanty P. Potential use of insulin as an anti-inflammatory drug.  Drug Develop Res. 2008;  69 101-110
• 75 Chaudhuri A, Janicke D, Wilson MF, Tripathy D, Garg R, Bandyopadhyay A, Calieri J, Hoffmeyer D, Syed T, Ghanim H, Aljada A, Dandona P. Anti-inflammatory and profibrinolytic effect of insulin in acute st-segment–elevation myocardial infarction.  Circulation. 2008;  109 849-854
• 76 Bretzel RG, Nuber U, Landgraf W, Owens DR, Bradley C, Linn T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomized controlled trial.  Lancet. 2008;  371 1073-1084
• 77 Mathieu C, Robberecht S. Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients.  Diabetes Obes Metab. 2008;  10 ((Suppl 2)) 14-23
• 78 Yki-Jarvinen H, Dressler A, Ziemen M. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.  Diabetes Care. 2000;  23 1130-1136
• 79 Riddle MC. The treat-to-target trial and related studies.  Endocr Pract. 2006;  12 ((Suppl 1)) 71-79
• 80 Rosenstock J, Schwartz SL, Clark Jr CM, Park GD, Donley DW, Edwards MB. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin.  Diabetes Care. 2001;  24 631-636
• 81 Schreiber S. Insulin glargine in type 2 diabetes in everyday clinical practice: 7 years on.  Diabetes Obes Metab. 2008;  10 ((Suppl 2)) 24-34
• 82 Janka HU. Insulin therapy in elderly patients with type 2 diabetes.  Diabetes Obes Metab. 2008;  10 ((Suppl 2)) 35-41
• 83 Dailey G. Beyond insulin replacement: addressing the additional needs of the diabetes patient.  Diabetes Obes Metab. 2008;  10 ((Suppl 2)) 85-99
• 84 Dailey G. Optimum management of type 2 diabetes – timely introduction, optimization and intensification of basal insulin.  Diabetes Obes Metab. 2008;  10 ((Suppl 2)) 5-13
• 85 Davies M, Khunti K. Insulin management in overweight or obese type 2 diabetes patients: the role of insulin glargine.  Diabetes Obes Metab. 2008;  10 ((Suppl 2)) 42-49
• 86 Davies M, Sinnassamy P, Storms F, Gomis R. on behalf of the AT.LANTUS Study Group . Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies.  Diabetes Res Clin Pract. 2008;  79 368-375
• 87 Hammer H, Klinge A. Patients with type 2 diabetes inadequately controlled on premixed insulin: effect of initiating insulin glargine plus oral antidiabetic agents on glycaemic control in daily practice.  Int J Clin Pract. 2007;  61 2009-2018
• 88 The ORIGIN Trial Investigators. . Gerstein H, Yusuf S, Riddle MC, Ryden L, Bosch J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: The ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention).  Am Heart J. 2008;  155 26.e1-26.e13
• 89 Schwartz S. Is there a rationale for insulin therapy in pre-diabetic individuals?.  Treat Endocrinol. 2006;  5 385-393
• 90 Schacky C von. A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.  Vasc Health Risk Manag. 2006;  2 251-262
• 91 Tsitouras PD, Gucciardo F, Salbe AD, Heward C, Harman SM. High omega-3 fat intake improves insulin sensitivity and reduces CRP and IL6, but does not affect other endocrine axes in healthy older adults.  Horm Metab Res. 2008;  40 199-205

Correspondence